Cargando…

Immune checkpoint blockade in triple negative breast cancer influenced by B cells through myeloid-derived suppressor cells

Triple negative breast cancer holds a dismal clinical outcome and as such, patients routinely undergo aggressive, highly toxic treatment regimens. Clinical trials for TNBC employing immune checkpoint blockade in combination with chemotherapy show modest prognostic benefit, but the percentage of pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vito, Alyssa, Salem, Omar, El-Sayes, Nader, MacFawn, Ian P., Portillo, Ana L., Milne, Katy, Harrington, Danielle, Ashkar, Ali A., Wan, Yonghong, Workenhe, Samuel T., Nelson, Brad H., Bruno, Tullia C., Mossman, Karen L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8275624/ https://www.ncbi.nlm.nih.gov/pubmed/34253827 http://dx.doi.org/10.1038/s42003-021-02375-9

Ejemplares similares

A Combination of Chemotherapy and Oncolytic Virotherapy Sensitizes Colorectal Adenocarcinoma to Immune Checkpoint Inhibitors in a cDC1-Dependent Manner
por: El-Sayes, Nader, et al.
Publicado: (2022)

Response to FEC Chemotherapy and Oncolytic HSV-1 Is Associated with Macrophage Polarization and Increased Expression of S100A8/A9 in Triple Negative Breast Cancer
por: Vito, Alyssa, et al.
Publicado: (2021)

IFNAR blockade synergizes with oncolytic VSV to prevent virus-mediated PD-L1 expression and promote antitumor T cell activity
por: El-Sayes, Nader, et al.
Publicado: (2022)

Combined Radionuclide Therapy and Immunotherapy for Treatment of Triple Negative Breast Cancer
por: Vito, Alyssa, et al.
Publicado: (2021)

Hypoxia-Driven Immune Escape in the Tumor Microenvironment
por: Vito, Alyssa, et al.
Publicado: (2020)

Tumor Heterogeneity: A Great Barrier in the Age of Cancer Immunotherapy
por: El-Sayes, Nader, et al.
Publicado: (2021)

De novo necroptosis creates an inflammatory environment mediating tumor susceptibility to immune checkpoint inhibitors
por: Workenhe, Samuel T., et al.
Publicado: (2020)

Oncolytic BHV-1 Is Sufficient to Induce Immunogenic Cell Death and Synergizes with Low-Dose Chemotherapy to Dampen Immunosuppressive T Regulatory Cells
por: Davola, Maria Eugenia, et al.
Publicado: (2023)

Type I interferons and related pathways in cell senescence
por: Frisch, Steven M., et al.
Publicado: (2020)

Mechanisms of PD-L1 Regulation in Malignant and Virus-Infected Cells
por: Farrukh, Hadia, et al.
Publicado: (2021)

Rewiring cancer cell death to enhance oncolytic viro-immunotherapy
por: Workenhe, Samuel T, et al.
Publicado: (2013)

Effect of Immune Checkpoint Blockade on Myeloid-Derived Suppressor Cell Populations in Patients With Melanoma
por: Sun, Steven H., et al.
Publicado: (2021)

Chemotherapy-induced recruitment of myeloid-derived suppressor cells abrogates efficacy of immune checkpoint blockade
por: Kwong, Tsz Tung, et al.
Publicado: (2020)

Targeting Myeloid-Derived Suppressor Cells to Enhance the Antitumor Efficacy of Immune Checkpoint Blockade Therapy
por: Li, Xueyan, et al.
Publicado: (2021)

Expanded human NK cells from lung cancer patients sensitize patients’ PDL1−negative tumors to PD1-blockade therapy
por: Poznanski, Sophie M, et al.
Publicado: (2021)

Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer
por: Camorani, Simona, et al.
Publicado: (2020)

Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade
por: Bommareddy, Praveen K., et al.
Publicado: (2019)

ESMO20 YO for YO: highlights on immune checkpoint blockade for triple-negative breast cancer
por: Punie, K., et al.
Publicado: (2020)

Immune Checkpoint Blockades in Triple-Negative Breast Cancer: Current State and Molecular Mechanisms of Resistance
por: Kim, Hyungjoo, et al.
Publicado: (2022)

Corticosteroids and immune checkpoint blockade
por: Min, Le, et al.
Publicado: (2015)

Immune checkpoint blockade in HIV
por: Gubser, Celine, et al.
Publicado: (2022)

Biomimetic nanoprobe-augmented triple therapy with photothermal, sonodynamic and checkpoint blockade inhibits tumor growth and metastasis
por: Lin, Xiaohong, et al.
Publicado: (2022)

Acetylation of Checkpoint suppressor 1 enhances its stability and promotes the progression of triple-negative breast cancer
por: Xu, Zhaowei, et al.
Publicado: (2022)

MCT4 blockade increases the efficacy of immune checkpoint blockade
por: Babl, Nathalie, et al.
Publicado: (2023)

Targeting CXCL16 and STAT1 augments immune checkpoint blockade therapy in triple-negative breast cancer
por: Palakurthi, Bhavana, et al.
Publicado: (2023)

Update on checkpoint blockade therapy for lymphoma
por: Kline, Justin, et al.
Publicado: (2015)

Immune checkpoint blockade in ovarian cancer
por: Weiss, Lukas, et al.
Publicado: (2016)

LIGHTing tumor up for checkpoint blockade
por: Liang, Yong, et al.
Publicado: (2016)

Hallmarks of response to immune checkpoint blockade
por: Cogdill, Alexandria P, et al.
Publicado: (2017)

Immune-Checkpoint Blockade Therapy in Lymphoma
por: Kuzume, Ayumi, et al.
Publicado: (2020)

Activation of phagocytosis by immune checkpoint blockade
por: Li, Chia-Wei, et al.
Publicado: (2018)

Neutrophils in the era of immune checkpoint blockade
por: Faget, Julien, et al.
Publicado: (2021)

Increased FDG avidity in lymphoid tissue associated with response to combined immune checkpoint blockade
por: Tsai, Katy K., et al.
Publicado: (2016)

Decoding cancer’s camouflage: epithelial-mesenchymal plasticity in resistance to immune checkpoint blockade
por: Lotsberg, Maria L., et al.
Publicado: (2020)

Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade
por: Grauers Wiktorin, Hanna, et al.
Publicado: (2018)

Inhibiting the inhibitors: Checkpoints blockade in solid tumors
por: Mavilio, Domenico, et al.
Publicado: (2013)

Immune-Checkpoint Blockade and Active Immunotherapy for Glioma
por: Ahn, Brian J., et al.
Publicado: (2013)

The Puzzle of Predicting Response to Immune Checkpoint Blockade
por: Onyshchenko, Mykola
Publicado: (2018)

Smoldering myocarditis following immune checkpoint blockade
por: Norwood, Timothy G., et al.
Publicado: (2017)

Diagnosis and Management of Hepatitis in Patients on Checkpoint Blockade
por: Reynolds, Kerry, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ca6uhc23krcuequkf1pdghcjfp